Roche has launched its next-generation portfolio SARS-CoV-2 rapid antigen tests (“2.0”) for self-testing and professional use in countries accepting the CE mark.
studiocriacao Shutterstock
1933491686
Covid-19
In doing so, Roche builds upon its portfolio of COVID-19 rapid testing solutions with three new test configurations that feature an improved capture antibody and the addition of new digital data sharing capabilities to all tests. Using nasopharyngeal and nasal swab samples, respectively, the tests deliver results in as few as 15 minutes, aiding in the diagnosis of SARS-CoV-2 infection in individuals with or without symptoms consistent with COVID-19.
Thomas Schinecker, CEO, Roche Diagnostics, said: “The continued evolution of the SARS-CoV-2 virus and COVID-19 pandemic reinforce the need for individuals and healthcare systems to have access to the most reliable rapid testing solutions possible. As a leader in diagnostic innovation, we are proud to be one of the first among our industry to apply insights gained from the past two years toward a next-generation rapid test portfolio. These tests are ready to support global society as we navigate this next phase of the pandemic.”
The three tests set to launch are the following:
Professional use:
- SARS-CoV-2 Rapid Antigen Test 2.0 (nasopharyngeal sampling)
- SARS-CoV-2 Rapid Antigen Test 2.0 Nasal (nasal sampling)
Self-Test:
- SARS-CoV-2 Antigen Self Test Nasal (nasal sampling)
A spokesperson for Roche Diagnostics UK and Ireland, said: “We know this winter will be incredibly challenging for the NHS, with a likely surge in both flu and COVID-19 cases, and it is critical that individuals and clinicians have access to the most reliable tests for both.
“From the early stages of the pandemic, Roche is proud to have supported the national response, having developed the world’s first PCR test in March 2020. The launch of our next-generation rapid antigen tests is the latest in a long line of solutions we have delivered, and we stand ready to do all we can to help the NHS during this very challenging time.”
